Table 2.

TIL in HER2+ tumors according to different clinical trials

Studies	APT trial	N9831 trial	NeoSphere trial	Pooled analysis of GEPAR trials	NeoALTTO trial	PAMELA trial	TRYPHAENA trial
Number of patients	284 patients	945 patients	350 patients	1379 patients	387 patients	148 patients	213 patients
Disease setting	Adjuvant	Adjuvant	Neoadjuvant	Neoadjuvant	Neoadjuvant	Neoadjuvant	Neoadjuvant
HR+ tumors, %	68	54	46	53	50	52	50
Node negative tumors, %	100	14	28	40	NR	64	29
Tumors measuring ≤ 2 cm, %	89	39	0	12	2	40	0
TIL as categories	≤10%: 65%	0–9%: 33.7%	0–5%: 13.6%	≤10%: 44%	NR	NR	NR
	10–60%: 28%	10–60%: 56.5%	5–50%: 69.5%	10–60%: 37%
	≥60%: 7%	≥60%: 9.9%	>50%: 16.9%	≥60%: 19%
TIL as median (IQR)	5% (5–20%)	NR	NR	NR	12.5% (5–30%)	10% (5–20%)	14% (7–32%)

TIL, tumor-infiltrating lymphocytes; HR+, hormone-receptor positive; IQR, interquartile range; NR, not reported.